TargED raises €21.5 million Series A extension to accelerate clinical development of targeted thrombolytic therapy (Alumni news)
TargED Biopharmaceuticals B.V., a clinical-stage biotechnology company developing next-generation targeted treatments for thrombotic diseases, has secured a €21.5 million Series A extension, bringing its total Series A funding to over €60 million.
The financing round was led by Dutch life sciences venture capital firm BioGeneration Ventures (BGV), with continued participation from existing investors Andera Partners, Fund+, Hadean Ventures, Inkef Capital, Sunstone Life Science Ventures and Curie Capital.
The new capital will be used to accelerate the clinical development of TGD001, TargED’s first-in-class targeted thrombolytic therapy. TGD001 is designed to treat a broad range of thrombotic events by targeting both von Willebrand factor (VWF) and fibrin, enabling site-specific clot breakdown. With this funding, TargED will initiate two Phase 1/2 clinical trials across Europe and the United States, with first clinical data expected in 2026.
In December 2025, TargED reported positive results from its Phase 1 first-in-human study, demonstrating a favourable safety profile with no spontaneous bleeding events and showing potent thrombolytic activity. These results were presented during an oral session at the American Society of Hematology (ASH) Annual Meeting.
According to TargED, the Series A extension marks an important step toward advancing TGD001 into later-stage clinical development and expanding clinical trial activities internationally.
TargED Biopharmaceuticals was founded in 2020 as a spin-off from University Medical Center Utrecht and focuses on targeted enzyme delivery approaches for the treatment of thrombotic diseases. In 2025, the company also received a blended finance grant from the European Innovation Council (EIC) Accelerator.
Investor syndicate: Andera Partners, BioGeneration Ventures, Fund+, Hadean Ventures, Inkef Capital, Sunstone Life Science Ventures, Curie Capital, FIRST, and Utrecht Health Seed Fund.
Read the full press release: https://lnkd.in/eaDtCQUr
